ClearBridge Large Cap Growth Strategy on Thermo Fisher Scientific
Thesis
Thermo Fisher Scientific offers exposure to an improving life sciences investment cycle following a challenging period for industry spending. Its second-quarter earnings beat demonstrated resilience across biopharma consumables and pharmaceutical product development markets. Healthy third-quarter guidance supports ClearBridge's expectation that the business could accelerate into 2027. The managers particularly value the breadth of recovery across the company's end markets.
“The breadth of recovery across those end markets is particularly important after a more difficult period for life sciences spending.”
Key risks
- Renewed weakness in life sciences spending could interrupt the recovery.
- Slower biopharma consumables demand could undermine earnings expectations.
- A weaker pharmaceutical product development market could delay acceleration into 2027.